The peptide saga took a concrete step in April: roughly a dozen peptides were moved off the FDAs restricted Category 2 list. But removal is not the same as approval, or even legal compounding, yet.
In April 2026, roughly a dozen peptides, including BPC-157 and TB-500, were moved off the FDAs restricted Category 2 compounding list. But removal from Category 2 does not automatically grant Category 1 status, is not FDA approval, and does not by itself authorize compounding; each peptide still requires individual advisory-committee review, expected to begin in July 2026.
After February signal and March uncertainty, April brought a concrete, if narrow, step in the peptide story.
But the nuance remained as important as the headline.
In mid-April 2026, federal officials confirmed the removal of about a dozen peptides, including BPC-157, TB-500, MOTS-c, and others, from the FDAs Category 2 restricted compounding list, reportedly tied to the withdrawal of the nominations that had placed them there. Coverage emphasized a critical distinction: being removed from Category 2 does not automatically place a peptide in Category 1 (eligible for compounding), nor does it constitute FDA approval. Each substance still requires individual review.
Reporting indicated the FDAs Pharmacy Compounding Advisory Committee was scheduled to begin evaluating specific peptides, including BPC-157, in July 2026, with additional peptides to follow, and that formal rulemaking would be required before compounding pharmacies could act. Some senior officials reportedly had reservations about moving on political rather than purely scientific grounds. In short: a real procedural step, but not a finish line.
For consumers, April underscored how layered this process is. Three different things, removal from the restricted list, eligibility for compounding (Category 1), and FDA approval of a drug, are easily blurred in headlines, and none of them means a peptide is proven, approved, or freely available. The persistent gray market of research-only online peptides remains unregulated and risky regardless of these procedural moves.
The decisive milestones are the advisory-committee reviews beginning in July 2026 and any formal FDA rulemaking that follows, which would determine whether and how licensed pharmacies may compound specific peptides. Until then, status remains in flux. Consumers should follow official FDA communications rather than vendor claims, and treat any seller asserting these peptides are now legal or approved because of the April removal with skepticism.